Equities

Revance Therapeutics Inc

Revance Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.70
  • Today's Change-2.08 / -35.99%
  • Shares traded13.15m
  • 1 Year change-55.58%
  • Beta0.8366
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments254341225
Total Receivables, Net28113.35
Total Inventory461810
Prepaid expenses114.367.54
Other current assets, total0.55----
Total current assets339375246
Property, plant & equipment, net906869
Goodwill, net077147
Intangibles, net9.812755
Long term investments------
Note receivable - long term------
Other long term assets0.321.698.70
Total assets478582531
LIABILITIES
Accounts payable144.5511
Accrued expenses565743
Notes payable/short-term debt000
Current portion long-term debt/capital leases5.150.67--
Other current liabilities, total141314
Total current liabilities897667
Total long term debt427379281
Total debt432380281
Deferred income tax------
Minority interest------
Other liabilities, total114114115
Total liabilities630569463
SHAREHOLDERS EQUITY
Common stock0.090.080.07
Additional paid-in capital1,9271,7671,466
Retained earnings (accumulated deficit)(2078)(1754)(1398)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.01(0.37)(0.02)
Total equity(152)1368
Total liabilities & shareholders' equity478582531
Total common shares outstanding888272
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.